Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Metastatic Prostate Cancer
NCT07333976Phase 2Completed
- Sponsor
- Tri-Service General Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tadalafil in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Tri-Service General Hospital. Started Jan 2020; status: completed.
02
Drugs
tadalafil
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07333976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333976.